AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16963349 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling
Number of subjects: 9
Study 16963349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9
Study 12600846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% of energy, n = 19)
Number of subjects: 37
Study 12600846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat diet (46% of energy, 41% of energy from fat, n = 18)
Number of subjects: 37
Study 10962425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.4 microg/kg)
Number of subjects: 14
Study 10962425 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution placebo or no treatment)
Number of subjects: 14
Study 8993100 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Venous Insufficiency Questionnaire (CIVIQ)
Number of subjects: 934
Study 1289138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate instillation before refraction
Number of subjects: 100
Study 3936031 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin treatment
Number of subjects: 29
Study 31070763 — intervention group
Group type: EXPERIMENTAL
Intervention: modulated electro-hyperthermia (mEHT) treatment at a maximal applied power of 150 W for 1 hour/day
Number of subjects: 19
Study 29801011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of gemcitabine (2 g in 100 mL of saline)
Number of subjects: 406
Study 29801011 — intervention group
Group type: COMPARATOR
Intervention: Saline (100 mL)
Number of subjects: 406
Study 27166360 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg orally 3 times weekly
Number of subjects: 40
Study 27166360 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat with rituximab
Number of subjects: 40
Study 24084467 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored self-help intervention
Number of subjects: 0
Study 24084467 — intervention group
Group type: COMPARATOR
Intervention: Generic self-help intervention
Number of subjects: 0
Study 22250656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (480 mg DHA/720 mg EPA)
Number of subjects: 41
Study 22250656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (coconut oil)
Number of subjects: 41
Study 20704105 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (22 patients, 92 screws)
Number of subjects: 42
Study 20704105 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic control (20 patients, 84 screws)
Number of subjects: 42
Study 20704105 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation
Number of subjects: 42
Study 17433019 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 biopsies per endoscopy with H&E staining
Number of subjects: 125
Study 17433019 — intervention group
Group type: COMPARATOR
Intervention: 4 biopsies per endoscopy with H&E staining
Number of subjects: 125
Study 17433019 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 16 biopsies per endoscopy with H&E staining
Number of subjects: 125
Study 17433019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcian blue/periodic‐acid Schiff staining
Number of subjects: 125
Study 15901516 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 1295
Study 15901516 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led intervention
Number of subjects: 1295
Study 12432968 — intervention group
Group type: COMPARATOR
Intervention: Dapsone 100 mg alone
Number of subjects: 16
Study 12432968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg plus nizatidine 300 mg
Number of subjects: 16
Study 10597555 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 88
Study 8619521 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 54
Study 8619521 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (NEX)
Number of subjects: 54
Study 1849442 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy (high-dose epirubicin)
Number of subjects: 12
Study 1849442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, epirubicin, and etoposide)
Number of subjects: 12
Study 1849442 — intervention group
Group type: COMPARATOR
Intervention: Both treatment modalities
Number of subjects: 12
Study 1849442 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epirubicin
Number of subjects: 12
Study 7093924 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy (MACC: methotrexate, doxorubicine hydrochloride, cyclophosphamide, and lomustine)
Number of subjects: 39
Study 7093924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7093924 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy (MACC)
Number of subjects: 39
Study 31573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode-tailored website (textual, visual, audiovisual modes)
Number of subjects: 232
Study 31573911 — intervention group
Group type: COMPARATOR
Intervention: Nontailored website (text only, text with images, text with videos)
Number of subjects: 232
Study 31573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode-tailored website
Number of subjects: 232
Study 31573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge before consultation (T1)
Number of subjects: 232
Study 31573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on the website (T1)
Number of subjects: 232
Study 31573911 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge from the website afterward (T3)
Number of subjects: 232
Study 30071821 — intervention group
Group type: EXPERIMENTAL
Intervention: Victoria intervention (three half‐day training sessions and bi‐monthly supervision meetings for 18 months)
Number of subjects: 0
Study 30071821 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 26891418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir and ribavirin for 12 or 24 weeks
Number of subjects: 0
Study 26891418 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors associated with HCV RNA <LLOQ at week 2
Number of subjects: 0
Study 26891418 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors associated with HCV RNA <LLOQ at week 4
Number of subjects: 0
Study 26891418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early on-treatment HCV RNA
Number of subjects: 0
Study 24950920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume with PEEP (tidal volume = 6 mL/kg, rate = 18/minute, PEEP = 5 cm H(2)O)
Number of subjects: 60
Study 24950920 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (tidal volume = 10 mL/kg, rate = 12/minute, PEEP = 0 cm H(2)O)
Number of subjects: 60
Study 24950920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low tidal and conventional)
Number of subjects: 60
Study 24950920 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 60
Study 24950920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal group
Number of subjects: 60
Study 24950920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 21598243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ixabepilone and capecitabine (once every 21 days)
Number of subjects: 752
Study 21598243 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (on days 1-14)
Number of subjects: 752
Study 19174497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg/d)
Number of subjects: 0
Study 19174497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS 55 (G45:F55)
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: G20:F80
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: G35:F65
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: G50:F50
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: G80:F20
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose solutions
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose solutions
Number of subjects: 31
Study 17991646 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and BG AUCs
Number of subjects: 31
Study 17991646 — intervention group
Group type: COMPARATOR
Intervention: Sweet energy-free control (experiment 1)
Number of subjects: 31
Study 17991646 — intervention group
Group type: COMPARATOR
Intervention: Water (both experiments)
Number of subjects: 31
Study 15342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (7.5 mg)
Number of subjects: 12
Study 15342619 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular lorazepam (4 mg)
Number of subjects: 12
Study 11334193 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits
Number of subjects: 39
Study 11334193 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-bonded circuits
Number of subjects: 39
Study 9587048 — intervention group
Group type: EXPERIMENTAL
Intervention: benfotiamin
Number of subjects: 7
Study 9587048 — intervention group
Group type: EXPERIMENTAL
Intervention: fursultiamin
Number of subjects: 7
Study 9587048 — intervention group
Group type: EXPERIMENTAL
Intervention: thiaminedisulfide
Number of subjects: 7
Study 8017465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg with the evening meal
Number of subjects: 44
Study 8017465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg at bedtime
Number of subjects: 44
Study 8017465 — intervention group
Group type: COMPARATOR
Intervention: Placebo at mealtime and at bedtime
Number of subjects: 44
Study 2574115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study 2574115 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg
Number of subjects: 10
Study 2574115 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 120 mg
Number of subjects: 10
Study 1277740 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of methylglucamine iodipamide
Number of subjects: 50
Study 1277740 — intervention group
Group type: COMPARATOR
Intervention: Single bolus injection of methylglucamine iodipamide
Number of subjects: 50
Study 1277740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (infusion and single bolus)
Number of subjects: 50
Study 31260843 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐Bundle‐Lateral‐Plasty (SBLP)
Number of subjects: 42
Study 31260843 — intervention group
Group type: COMPARATOR
Intervention: Single Bundle (SB)
Number of subjects: 42
Study 31260843 — intervention group
Group type: COMPARATOR
Intervention: Double Bundle (DB)
Number of subjects: 42
Study 28600833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (App, n=42)
Number of subjects: 81
Study 28600833 — intervention group
Group type: COMPARATOR
Intervention: Wearable Bite Counter device (Bite, n=39)
Number of subjects: 81
Study 28600833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (App)
Number of subjects: 81
Study 28600833 — intervention group
Group type: COMPARATOR
Intervention: Wearable Bite Counter device (Bite)
Number of subjects: 81
Study 25636814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBVT + L-citrulline
Number of subjects: 41
Study 25636814 — intervention group
Group type: COMPARATOR
Intervention: All interventions (WBVT, L-citrulline, WBVT + L-citrulline)
Number of subjects: 41
Study 25636814 — intervention group
Group type: COMPARATOR
Intervention: Both WBVT interventions (WBVT and WBVT + L-citrulline)
Number of subjects: 41
Study 23065090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily for 4 weeks
Number of subjects: 70
Study 23065090 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg daily for 4 weeks
Number of subjects: 70
Study 22035999 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Number of subjects: 78
Study 18829112 — intervention group
Group type: EXPERIMENTAL
Intervention: Average team member Openness to Experience
Number of subjects: 159
Study 18829112 — intervention group
Group type: EXPERIMENTAL
Intervention: Average team member Conscientiousness
Number of subjects: 159
Study 18829112 — intervention group
Group type: EXPERIMENTAL
Intervention: Average team member Agreeableness
Number of subjects: 159
Study 16835031 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (gentle rubbing, stroking, passive movements of the limbs) performed by professionals until the infant is 8 months old
Number of subjects: 50
Study 16835031 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 50
Study 16835031 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy LBW infants)
Number of subjects: 50
Study 15577227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin-to (6.0 g, single oral administration)
Number of subjects: 5
Study 15577227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 11387994 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 11387994 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF patients
Number of subjects: 0
Study 9247407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (24‐hour low‐tryptophan diet and ingestion of a tryptophan‐free amino acid beverage)
Number of subjects: 11
Study 9247407 — intervention group
Group type: COMPARATOR
Intervention: Control testing (diet and beverage supplemented with tryptophan)
Number of subjects: 11
Study 9247407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 11
Study 9247407 — intervention group
Group type: COMPARATOR
Intervention: Control testing
Number of subjects: 11
Study 8286514 — intervention group
Group type: EXPERIMENTAL
Intervention: One day course of ampicillin and metronidazole
Number of subjects: 88
Study 8286514 — intervention group
Group type: COMPARATOR
Intervention: Four day course of ampicillin and metronidazole
Number of subjects: 88
Study 3087617 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) at 60 mg/m2, Ifosfamide (IFF) at 7500 mg/m2, Dacarbazine (DTIC) at 900 mg/m2 by continuous infusion over 72 hours
Number of subjects: 20
Study 3087617 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) by continuous infusion
Number of subjects: 20
Study 3087617 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)
Number of subjects: 20
Study 3087617 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX), Ifosfamide (IFF), Dacarbazine (DTIC)
Number of subjects: 20
Study 31943737 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment assignment with a biomarker measurement
Number of subjects: 0
Study 31943737 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent logistic model for treatment response
Number of subjects: 0
Study 29546305 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nutritional dose of antioxidant supplement (120 mg vitamin C, 6 mg β-carotene, 30 mg vitamin E, 100 μg Se, 20 mg Zn)
Number of subjects: 2796
Study 29546305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2796
Study 28209452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 moments for patient hand hygiene educational intervention
Number of subjects: 0
Study 26698262 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg ticagrelor
Number of subjects: 74
Study 26698262 — intervention group
Group type: COMPARATOR
Intervention: 600 mg clopidogrel
Number of subjects: 74
Study 24040848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene with high-fat breakfast (860 kcal)
Number of subjects: 24
Study 24040848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene with low-fat breakfast (300 kcal)
Number of subjects: 24
Study 24040848 — intervention group
Group type: COMPARATOR
Intervention: Ospemifene without food (overnight fast)
Number of subjects: 24
Study 24040848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolution in fed intestinal fluid
Number of subjects: 24
Study 21438929 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 26
Study 21438929 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 21438929 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CSF L‐PGDS
Number of subjects: 26
Study 21438929 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of CSF L‐PGDS after weight loss
Number of subjects: 26
Study 21438929 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum L‐PGDS
Number of subjects: 26
Study 17967218 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacultured salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Number of subjects: 28
Study 17967218 — intervention group
Group type: COMPARATOR
Intervention: Wild salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Number of subjects: 28
Study 16832316 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 1610
Study 15319047 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth intervention
Number of subjects: 104
Study 15319047 — intervention group
Group type: COMPARATOR
Intervention: Usual home healthcare services (Control)
Number of subjects: 104
Study 11467624 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) over 4 weeks
Number of subjects: 1143
Study 9015888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan treatment
Number of subjects: 0
Study 9015888 — intervention group
Group type: COMPARATOR
Intervention: Western treatment
Number of subjects: 0
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia (2.5 mM)
Number of subjects: 10
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia with combined α‐ and β‐ adrenergic blockade (phentolamine and propranolol)
Number of subjects: 10
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia with panautonomic blockade (phentolamine, propranolol and atropine)
Number of subjects: 10
Study 8243825 — intervention group
Group type: COMPARATOR
Intervention: Clamped euglycemia (5 mM)
Number of subjects: 10
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic symptoms (adrenergic)
Number of subjects: 10
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic symptoms (cholinergic)
Number of subjects: 10
Study 8243825 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroglycopenic symptoms
Number of subjects: 10
Study 2945704 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent clindamycin phosphate lotion
Number of subjects: 46
Study 2945704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 28948645 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (50 mg/d)
Number of subjects: 147
Study 28948645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 27909120 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral reaming technique
Number of subjects: 0
Study 27909120 — intervention group
Group type: COMPARATOR
Intervention: Standard reaming technique
Number of subjects: 0
Study 24351079 — intervention group
Group type: EXPERIMENTAL
Intervention: OC/APAP ER
Number of subjects: 329
Study 24351079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 23098480 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 612
Study 23098480 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about cervical cancer and HPV vaccine
Number of subjects: 612
Study 23098480 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing HPV vaccine uptake
Number of subjects: 612
Study 20335115 — intervention group
Group type: EXPERIMENTAL
Intervention: PGEl + ACEI
Number of subjects: 0
Study 20335115 — intervention group
Group type: EXPERIMENTAL
Intervention: PGEl
Number of subjects: 0
Study 20335115 — intervention group
Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 0
Study 20335115 — intervention group
Group type: COMPARATOR
Intervention: Basal treatment (Control group)
Number of subjects: 0
Study 18752509 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved tafluprost 0.0015% eyedrops
Number of subjects: 0
Study 18752509 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free tafluprost 0.0015% eyedrops
Number of subjects: 0
Study 18752509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study 11380317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg or 20 mg)
Number of subjects: 18
Study 11380317 — intervention group
Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study 9691892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Spin Echo Proton Density (FSE PD)
Number of subjects: 116
Study 9691892 — intervention group
Group type: COMPARATOR
Intervention: Spin Echo T1 (SE T1)
Number of subjects: 116
Study 7938668 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar and/or distinctive cues
Number of subjects: 0
Study 7938668 — intervention group
Group type: COMPARATOR
Intervention: 3-minutes' delay between instructions and task
Number of subjects: 0
Study 7938668 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual distinctiveness
Number of subjects: 0
Study 7938668 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled delay with demanding interpolated activity (practice in a STM task)
Number of subjects: 0
Study 7938668 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled delay with undemanding motoric activity (repetitive hands movements)
Number of subjects: 0
Study 7938668 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfilled delay with undemanding verbal activity (counting)
Number of subjects: 0
Study 2851179 — intervention group
Group type: COMPARATOR
Intervention: Etoposide (single-agent)
Number of subjects: 216
Study 2851179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (VP-16)
Number of subjects: 216